Journal
CLINICAL CANCER RESEARCH
Volume 27, Issue 6, Pages 1612-1622Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-1831
Keywords
-
Categories
Funding
- Puma Biotechnology, Inc.
- NCI [P30 CA047904, R50 CA211241]
- NSABP Foundation, Inc.
Ask authors/readers for more resources
This study aimed to determine the recommended phase II dose and efficacy of neratinib combined with cetuximab in patients with metastatic colorectal cancer, particularly those who were resistant to anti-EGFR therapy. The study found that the recommended dose of neratinib in this combination therapy was well tolerated with a low incidence of adverse events, and while there were no objective responses, stable disease was observed at all neratinib doses. Additionally, HER2 amplification was more frequently detected in tissue and blood samples post-anti-EGFR therapy.
Purpose: In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combined with cetuximab, in patients with progressive disease (PD) on anti-EGFR treatment. Patients and Methods: Twenty-one patients with quadruple-wild-type, refractory mCRC enrolled in this 3+3 phase Ib study. Standard dosage cetuximab was administered with neratinib at 120 mg, 160 mg, 200 mg, and 240 mg/day orally in 28-day cycles. Samples were collected for molecular and pharmacokinetic studies. Results: Sixteen patients were evaluable for dose-limiting toxicity (DLT). 240 mg was determined to be the RP2D wherein a single DLT occurred (1/7 patients). Treatment-related DLTs were not seen at lower doses. Best response was stable disease (SD) in 7 of 16 (44%) patients. HER2 amplification (chromogenic in situ IHC) was detected in 2 of 21 (9.5%) treatment-naive tumors and 4 of 16 (25%) biopsies upon trial enrollment (post-anti-EGFR treatment and progression). Compared with matched enrollment biopsies, 6 of 8 (75%) blood samples showed concordance for HER2 CNV in circulating cell-free DNA. Five SD patients had HER2 amplification in either treatment-naive or enrollment biopsies. Examination of gene-expression, total protein, and protein phosphorylation levels showed relative upregulation of >= 2 members of the HER-family receptors or ligands upon enrollment versus matched treatment-naive samples. Conclusions: The RP2D of neratinib in this combination was 240 mg/day, which was well tolerated with low incidence of G3 AEs. There were no objective responses; SD was seen at all neratinib doses. HER2 amplification, detectable in both tissue and blood, was more frequent post-anti-EGFR therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available